Does TAFASITAMAB Cause Malignant neoplasm progression? 47 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 47 reports of Malignant neoplasm progression have been filed in association with TAFASITAMAB (MONJUVI). This represents 3.4% of all adverse event reports for TAFASITAMAB.
47
Reports of Malignant neoplasm progression with TAFASITAMAB
3.4%
of all TAFASITAMAB reports
17
Deaths
12
Hospitalizations
How Dangerous Is Malignant neoplasm progression From TAFASITAMAB?
Of the 47 reports, 17 (36.2%) resulted in death, 12 (25.5%) required hospitalization, and 4 (8.5%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TAFASITAMAB. However, 47 reports have been filed with the FAERS database.
What Other Side Effects Does TAFASITAMAB Cause?
Disease progression (470)
Diffuse large b-cell lymphoma (346)
Off label use (203)
Death (146)
Neutropenia (99)
Covid-19 (96)
General physical health deterioration (75)
Pneumonia (66)
Febrile neutropenia (64)
Drug ineffective (62)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which TAFASITAMAB Alternatives Have Lower Malignant neoplasm progression Risk?
TAFASITAMAB vs TAFASITAMAB-CXIX
TAFASITAMAB vs TAFINLAR
TAFASITAMAB vs TAFLUPROST
TAFASITAMAB vs TAGRAXOFUSP-ERZS
TAFASITAMAB vs TAHOR